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Cell cycleThe homeobox transcription factor PROX1 is essential for the development and maintenance of lymphatic
vasculature. How PROX1 regulates lymphatic endothelial cell fate remains undeﬁned. PROX1 has been shown
to upregulate the expression of Cyclin E, which mediates the G1 to S transition of the cell cycle. Here we
demonstrate that PROX1 activates the mouse Cyclin E1 (Ccne1) promoter via two proximal E2F-binding sites.
We have determined that the N-terminal region of PROX1 is sufﬁcient to activate a 1-kb Ccne1 promoter,
whereas the homeodomain is dispensable for activation. We have identiﬁed that the Prospero domain 1 (PD1)
is required for the nuclear localization of PROX1. Our comparison of two DNA-binding-deﬁcient constructs of
PROX1 showed a cell-type-speciﬁc difference between these two proteins in both their localization and
function. We demonstrated that siRNA-mediated knockdown of PROX1 in lymphatic endothelial cells
decreases progression from G1 to S phase of the cell cycle. We conclude that PROX1 activates the Ccne1
promoter independent of DNA binding, and our results illustrate a novel role for PROX1 in the regulation of
lymphatic endothelial cell proliferation.nipeg, Manitoba, Canada. Tel.:
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In Drosophila melanogaster, the homeobox gene prospero controls
many key cellular processes such as asymmetric cell division,
axonogenesis, and sensory organ development [1]. The mammalian
ortholog of prospero is Prox1 (Prospero-related homeobox gene-1),
which is essential for the proper development of the murine lens,
liver, pancreas, and lymphatic system [2–7]. All homeobox genes
encode a 60-amino-acid motif known as the homeodomain that binds
to the major groove of genomic DNA [8]. In addition to DNA binding,
the homeodomain also regulates transcriptional activity by mediating
protein–protein interactions [9–11].
The blood and lymphatic vessels share common developmental
origins, but the endothelial cells of these two related systems are
functionally andmolecularly distinct [12,13]. Florence Sabin proposed
that blood vessels develop ﬁrst and that the lymphatic vessels sprout
from these early embryonic veins [14]. At embryonic day (E) 9.5 in
mouse, a subset of the blood endothelial cells (BECs) within thecardinal vein begin to express Prox1 [5]. These Prox1 expressing cells
migrate out of the cardinal vein, differentiate into lymphatic
endothelial cells (LECs), and then continue to proliferate, thereby
forming the lymphatic vessels [15]. Prox1 is essential for lymphatic
development as Prox1 null mice are completely devoid of lymphatics
[5]. In vivo, Prox1 null murine endothelial cells, which would normally
be destined to become LECs, aberrantly express BEC markers, such as
laminin and collagen IV, and also fail to properly express lymphatic
endothelial cell markers such as VEGFR-3 and LYVE-1 [15]. Recently,
PROX1 has been shown to be required for the maintenance of the LEC
phenotype in adult lymphatic vessels [16]. Furthermore, viral
transduction of Prox1 into venous endothelial cells is sufﬁcient to
activate transcription of lymphatic speciﬁc genes (VEGFR-3/Podopla-
nin) and to repress transcription of blood endothelial cell genes
(Neuropilin-1) [17,18]. These ﬁndings support a key role for Prox1 as a
cell fate switch that regulates and maintains the differentiation of
lymphatic endothelial cells.
Prox1 encodes a 737-amino-acid transcription factor with a
predicted molecular weight of 83 kDa that contains several putative
functional domains in addition to its homeodomain (Fig. 1A). The
amino terminus (N-) of PROX1 contains two nuclear receptor boxes
(NR boxes) through which PROX1 associates with the ligand binding
202 S.A. Baxter et al. / Biochimica et Biophysica Acta 1813 (2011) 201–212domain of nuclear receptors [19–22]. The N-terminal region of PROX1
also contains its predicted nuclear localization sequence (NLS) and
the Prospero domain 1 (PD1), which is 45% conserved with the PD1
domain of the recently characterized PROX2 [23]. The carboxyl
terminal region of PROX1 is the most evolutionarily conserved regionof the protein. It contains a 60-amino-acid atypical homeodomain
(HD), which has a 3-amino-acid insertion between helix 2 and helix 3,
as well as a unique Prospero domain 2 (PD2), found in all Prox1
orthologs [3]. The PD2 domainmasks a nuclear export sequence (NES)
in the homeodomain, and its deletion results in the export of Prospero
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PROX1-mediated transcriptional regulation has not previously been
demonstrated. Together, the homeodomain and PD2 domain form a
continuous, hexa-helical homeoprospero domain [3,26] that binds to
the consensus sites (C(A/T)(C/T)NNC(T/C) and CGTCTT(A)) in the
major groove of DNA [27,28].
PROX1 regulation of transcription has been shown to be either
DNA-binding-dependent or DNA-binding-independent depending on
the particular gene under investigation [19–21]. Transcription of
cholesterol 7α-hydroxylase (CYP7α1), the gene encoding the rate-
limiting enzyme in bile acid synthesis, is repressed via PROX1 binding
to both hepatocyte nuclear factor-4α (HNF-4α) and liver receptor
homologue-1 (LRH-1) and not by PROX1 binding directly to DNA
[19,20]. Through protein–protein interactions, PROX1 binds to both
LRH-1 and HNF-4α via its NR boxes, particularly NR1 [19]. In contrast,
PROX1 directly binds to speciﬁc DNA consensus sequences in order to
the regulate the expression of ﬁbroblast growth factor receptor-3
(FGFR-3) and βB1 crystallin [21,29].
Recently, PROX1 has been shown to interact with the venous-
speciﬁc orphan nuclear receptor COUP-TFII in lymphatic endothelial
cells [30–32]. COUP-TFII is required for activation of PROX1 itself [32]
and throughmicroarray analysis has been shown to share many of the
same target genes as PROX1 in LECs [31]. Of these common targets,
both PROX1 and COUP-TFII have been shown to bind to the
endogenous Cyclin E1 promoter in primary LECs despite the lack of
consensus DNA-binding sites for either protein in the promoter region
[31]. Furthermore, loss-of-function studies in LECs showed that COUP-
TFII repressed Cyclin E1 expression, whereas PROX1 increased the
expression of Cyclin E1 [31].
Apparently, PROX1 has conﬂicting roles in cell cycle regulation.
PROX1 has been shown to induce cell cycle arrest in liver
hepatocellular carcinoma cells [33] but paradoxically it has been
shown to increase proliferation in fetal hepatoblasts [34]. Addition-
ally, PROX1 has been associated with the development of a dysplastic
form of human colon cancer [35]. These ﬁndings suggest that PROX1
regulates the cell cycle in a cell-type-dependent manner. Cyclin E1
was identiﬁed as a candidate downstream target of PROX1 in a cDNA
microarray study of venous endothelial cells infected with an
adenovirus encoding Prox1 [18]. Cyclin E1 is a key regulator of the
progression of the cell cycle from G1 into S phase [36]. Cyclin E1 binds
to cyclin-dependent kinase 2 (CDK2) to form an active complex that
phosphorylates the retinoblastoma protein (pRB), which in turn
releases the transcription factor E2F and thereby activates a set of E2F-
dependent genes required for transition into S phase.
The mouse Cyclin E1 (Ccne1) promoter contains a LRH-1-binding
site and multiple E2F-binding sites [37]. Two of these E2F-binding
sites are known to be required for Ccne1 regulation: one is located
upstream of the transcriptional start site and is constitutively bound,
whereas the other site is downstream of the start site and is only
occupied during G1 [37–39]. PROX1 activates transcription of a
reporter construct containing six tandem E2F (6xE2F) binding sites,
suggesting that PROX1 regulation of Ccne1 is via E2F-binding sites
[18]. In quiescent cells, pRB is found in a complex with E2F on the
Ccne1 promoter and recruits histone deacetylases (HDACs), which in
turn deacetylate the surrounding histones and repress Ccne1
transcription. PROX1 has previously been shown to directly bind to
and re-localize HDAC3 but not HDAC2 [22]. Taken together, theseFig. 1. Subcellular localization and expression levels of PROX1 protein constructs used in thi
terminal area of the protein consists of two nuclear receptor boxes (NR), the nuclear local
terminal of PROX1 is composed of the highly conserved homeodomain (HD), which contain
and the Prospero domain 2 together form the DNA-binding domain of PROX1. All of the
terminal FLAG epitope. Deletion constructs lacking both NR boxes (dblNRΔ), the PD1 doma
(HDPD2Δ) were generated. (B) In a representative Western blot, we show that on a cons
expressed in HEK 293 cells. (C–E) In transiently transfected U2OS cells, the expression of wil
in PROX1's localization to both the nucleus and the cytoplasm in all transfected cells. (F–H) U
the PD1Δ protein was retained in the nucleus indicating a potential role for the PD1 domaiﬁndings suggest a potential role for PROX1 in regulating transcription
of the Cyclin E1 promoter.
In this study, we demonstrate for the ﬁrst time that PROX1 is able
to activate the Ccne1 promoter independently of DNA binding. We
have identiﬁed that the Prospero domain 1 (PD1) is required for the
correct nuclear localization of PROX1. We also demonstrate that
PROX1 activates transcription of Ccne1 through two E2F sites adjacent
to the transcriptional start site in its promoter. siRNA-mediated
knockdown of PROX1 in lymphatic endothelial cells reduced the
expression of CCNE1 and also reduced the proportion of S phase cells.
We propose a role for PROX1 in mediating cell cycle regulation and
proliferation in lymphatic endothelial cells.
2. Materials and methods
2.1. Generation of Prox1 expression constructs
Amouse Prox1 cDNAclone (clone 6490801, Invitrogen)was digested
with EcoRI/SacII and the insert containing the Prox1 coding sequencewas
cloned into the EcoRI/SacII sites of the pBluescript II KS+ vector
(Stratagene). This plasmid was then used as a template for all other
Prox1 constructs used in this study. The FailSafe PCR kit (Epicentre) was
used to amplify these constructs in combination with the PCR splice
overlap extension technique [40] to generate the different Prox1
deletions or mutations (refer to Tables 1 and 3 in Supplementary
data). All versions of Prox1 were cloned into the SacII/XhoI sites of the
pCMV-Tag4A vector (Stratagene) and were therefore all tagged at their
carboxyl termini with the FLAG epitope (Fig. 1A).
2.2. Luciferase reporter constructs
One kilobase of the mouse Ccne1 promoter upstream of the
transcription start site (BAC genomic clone RP2377J9, Invitrogen) was
ampliﬁed (refer to Table 2 in the Supplementary Data) as previously
described [37] and cloned into the pCRBlunt vector (Invitrogen). All of
the deletion versions of the Ccne1 promoter were cloned into the
KpnI/BglII sites of the pGL3-basic reporter vector (Promega). The 220-
bp mouse FGFR-3 promoter in pGL2 was a kind gift from Dr. Ornitz
[41].
2.3. Cell culture
Human embryonic kidney (HEK) 293A cells (ATCC) were grown in
Dulbecco's modiﬁed Eagle's medium (DMEM) high glucose with L-
glutamine and sodium pyruvate (HyClone) supplemented with 5%
fetal bovine serum (Invitrogen) and 1% penicillin/streptomycin
(HyClone). U2-Osteosarcoma (U2OS) cells (ATCC, HTB-96) were
grown in McCoy's 5A medium (Invitrogen) supplemented with 10%
fetal bovine serum and 1% penicillin/streptomycin. Cells were
transiently transfected using the Lipofectamine 2000 reagent (Invi-
trogen) and were harvested for experiments 48 h post-transfection
with the exception of Fig. 1B, in which cells were harvested 24 h post-
transfection. Leptomycin B was purchased from Sigma-Aldrich, and
U2OS cells were treated with a ﬁnal concentration of 1 ng/ml in
normal growth media for 20 h at 37 °C as previously described [42].
Control cells were treated with the same volume of vehicle (70%
methanol). Human umbilical vein endothelial cells (HUVECs) (Lonza)s study. (A) This schematic highlights the known functional domains of PROX1: the N-
ization signal (NLS) as well as the conserved Prospero domain 1 (PD1) region. The C-
s the nuclear export signal (NES) and the Prospero domain 2 (PD2). The homeodomain
PROX1 expression constructs, including wild-type PROX1 (WT), contained a carboxyl
in (PD1Δ), the HD (HDΔ), the PD2 domain (PD2Δ), and both the HD and PD2 domain
istent basis, the HDPD2Δ version is more highly expressed than other versions when
d-type PROX1 is predominantly nuclear. In contrast, deletion of the PD1 domain results
pon treatment with the nuclear export inhibitor leptomycin B (LMB), we observed that
n in mediating PROX1 subcellular localization. Scale bar denotes 50 μM.
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growth factors (epidermal growth factor (EGF), vascular endothelial
growth factor (VEGF), insulin-like growth factor (IGF), basic ﬁbroblast
growth factor B (bFGF), heparin, ascorbic acid, hydrocortisone,
gentamicin sulphate, and amphotericin-B) and 2% fetal bovine
serum (Lonza). Cells were infected with adenovirus encoding either
WT Prox1 or a version in which the homeoprospero domain had been
deleted (HDPD2Δ) at a multiplicity of infection (MOI) of 250. The cells
were then harvested 48 h post-infection. Neonatal human dermal
lymphatic microvascular endothelial cells (LEC) (Lonza) were grown
in EBM-2 supplemented with growth factors (EGF, VEGF, IGF, FGF-B,
ascorbic acid, hydrocortisone, gentamicin sulphate, and amphoter-icin-B) and 10% fetal bovine serum (Lonza). Cells were transfected
with 100 μM of either ON-TARGETplus siCONTROL non-targeting or
PROX1 ON-TARGETplus SMART pool siRNAs (Dharmacon) using
DharmaFECT1 transfection reagent for 48 h as per the manufacturer's
instructions.
2.4. Immunocytochemistry
6–8×104 HEK 293 or U2OS cells were grown on glass coverslips in
6-well tissue culture plates (Becton Dickinson) for 48 h prior to
transfection. Forty-eight hours post-transfection, cells were ﬁxed in
4% paraformaldehyde (EM Science) for 30 min. Coverslips were then
washed with 1× phosphate-buffered saline (PBS) followed by washes
with 1× PBT (PBS with 0.3% Triton X-100) and were blocked in a 5%
normal goat serum-PBT solution. The cells were then incubated
overnight with anti-FLAG M2 monoclonal primary antibody (Sigma,
1:1000). The coverslips were washed in PBT and incubated with a
goat–anti-mouse secondary antibody coupled with Alexa Fluor 488
(Molecular Probes). The coverslips were then washed with 2× SSC
(0.3 M sodium chloride, 0.03 M sodium citrate, pH 7.0) and treated
with 100 μg/ml of RNase A (Sigma) for 30 min. The coverslips were
stained with propidium iodide (1:1000, Molecular Probes) for 15 min
and mounted onto glass slides. Images were captured with either an
Olympus light scanning confocal microscope equipped with FluoView
imaging software (Olympus) or a Zeiss 200 M light scanning confocal
microscope equipped with a digital camera and Pascal 5 imaging
software (Zeiss). Where immunocytochemistry results were quanti-
ﬁed, the observer was blinded to the identity of the slides.
2.5. Bromodeoxyuridine (BrdU) labeling
We employed 5′-bromo-2′-deoxyuridine (BrdU) (Fisher) labeling
in conjunction with DNA staining and measured the proportion of S
phase cells using ﬂow cytometry. 2.5×105 HUVECs were infected at
250 MOI with different adenoviral vectors and grown in 10-cm tissue
culture plates for 48 h prior to analysis. Alternatively, 3×105 LECs
were transfected with siRNA and allowed to grow for 24 h in
ﬁbronectin (Sigma) coated 6-well tissue culture plates. The cells
were then trypsinized and re-plated into ﬁbronectin coated 6-well
tissue culture plates at a lower density (1.5×105 cells per well) and
incubated for 24 h, 45 min prior to harvest, BrdU was added to each
well to a ﬁnal concentration of 100 μM and the plates were incubated
at 37 °C, 5% CO2. Cells were trypsinized and ﬁxed in ice-cold 70%
ethanol overnight at 4 °C. The cells were then pelleted at 200×g for
5 min at 4 °C and resuspended in 1 ml of freshly prepared 2 N HCl
(Fisher) and allowed to stand at room temperature for 25 min. Two
milliliters of 3% fetal bovine serum (FBS) in 1× PBS was added to each
sample, and the cells were pelleted at 200×g for 5 min at 4 °C. The
pellets were resuspended in 1 ml of sodium borate (Fisher) pH 8.5 and
incubated at room temperature for 2 min. Two milliliters of 3% FBS in
1× PBS was added to each sample, and the cells were pelleted atFig. 2. PROX1 activates the 1 kb Ccne1 promoter through a DNA-binding independent
mechanism. (A) Three PROX1 protein constructs that lack a functional DNA-binding
domain were generated and luciferase assays in HEK 293 cells were used to measure
the ability of these proteins to activate the 1 kb Ccne1 promoter in vitro. We observed
that all of the mutant proteins were able to signiﬁcantly activate the promoter,
although both the PD2Δ and HDPD2Δ proteins did not activate to the same extent as
theWT protein. (B) Deletion of both NR boxes (dblNRΔ) did not affect PROX1-mediated
activation of the 1 kb Ccne1 promoter. (C) Deletion of the PD1 domain (PD1Δ) resulted
in a signiﬁcant but modest decrease in induction of the 1 kb Ccne1 promoter as
compared toWT, but themutant protein still signiﬁcantly activated the promoter when
compared to the empty vector control. (D) In contrast, neither the HDΔ deletion
construct nor the 623WFEEFR628 DNA-binding mutant construct was able to
signiﬁcantly activate the 220-bp FGFR-3 promoter, which has been previously shown
to be regulated by PROX1 through a DNA-binding-dependent mechanism [22].
*Denotes a signiﬁcant difference from control, and #denotes a signiﬁcant difference
from WT at a p-valueb0.05.
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pellets were resuspended in 100 μl of 1× PBS containing 3% FBS and
10 μl of anti-BrdU Alexa 488-conjugated antibody (Molecular Probes)
and incubated for 2 h at room temperature. Twomilliliters of 3% FBS in
1× PBS was added, and the cells were pelleted at 200×g for 5 min at
4 °C. The pellets were subsequently resuspended in 500 μl of 3% FBS in
1× PBS containing 20 μl of 7-aminoactinomycin-D (7-AAD, Sigma)
and allowed to stand at room temperature for 15 min prior to
measuring on a BD FACSCalibur. 104 Gated cells were counted, and the
gates were arranged using the FL3-A vs. FL3-W plot to excludeFig. 3. Comparison of the transcriptional activities of two different PROX1 DNA-binding muta
to DNA. The novel 623WFEEFR628 mutant was compared to a previously published construct
DNA-binding-deﬁcient constructs were able to signiﬁcantly activate the 1-kb Ccne1 promot
activate the 1-kb Ccne1 promoter, whereas the 623WFSAFA628 version did not. In HEK 293 cell
protein was localized to both the cytoplasm and the nucleus (D). This cytoplasmic localizati
quantiﬁed this difference in an observer blinded manner and observed a signiﬁcant increase
PROX1 in U2OS cells (H). This cytoplasmic localization was much less pronounced in HEK 2doublets. The data were analyzed using CellQuest Pro software (BD
Biosciences) and quantiﬁed using Origin 8 software.
2.6. Western blotting
2×105 Cells grown in 6-cm plates were either transfected with
4 μg of DNA or infected with 250 MOI of adenovirus 48 h after plating.
These cells were lysed at 4 °C using New RIPA lysis buffer (50 mMTris,
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 1% sodium
desoxycholate, 0.1% SDS, pH 7.4) with a cocktail of protease inhibitorsnts. The sequence 623WFSNFR628 in the homeodomain of PROX1 is essential for binding
[18] in which this sequence was mutated to 623WFSAFA628. (A) In HEK 293 cells, both
er. (B) However, in U2OS cells, the 623WFEEFR628 version was still able to signiﬁcantly
s, the 623WFSAFA628 mutant was localized to the nucleus (C), whereas in U2OS cells, this
on was not observed for the 623WFEEFR628 mutant protein in either cell type (E, F). We
in the cytoplasmic localization of the 623WFSAFA628 mutant protein as compared toWT
93 cells (G).
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Roche) and centrifuged at 16,100×g for 5 min to pellet cell debris. A
standard protein assay was then performed using the DC standard
protein assay kit (Biorad) to ensure equal loading. The samples were
then prepared and denatured by heating at 95 °C for 5 min and loaded
onto SDS-polyacrylamide gels. After electrophoresis, the proteinswere transferred to a nitrocellulose membrane and the membranes
were then blocked in a 5% skim milk powder–Tris-buffered saline
(TBS) solution (5% Carnation Brand skim milk powder, 50 mM Tris,
140 mM NaCl, 2.7 mM KCl, pH 8) and probed with either the anti-
FLAG M2 monoclonal antibody (1:10,000, Sigma), anti-PROX1
polyclonal antibody (1:1000, Millipore), or an anti-CYCLIN E1
207S.A. Baxter et al. / Biochimica et Biophysica Acta 1813 (2011) 201–212monoclonal antibody (1:200, Santa Cruz Biotechnology). The blots
were then probed with a rabbit anti-actin antibody (1:10,000, Sigma)
to normalize protein loading. Images were captured using a Western
blot chemiluminescence kit (Santa Cruz Biotechnology) and either a
Fluor-S Max Imager (BioRad) or CL-Xposure blue X-ray ﬁlm (Thermo
Scientiﬁc).
2.7. Luciferase reporter assays
1×105 Cells were co-transfected with 1 μg of luciferase reporter
plasmid, 1 μg of pCMV-Tag4A encoding a version of Prox1 and 1 μg of
pcDNA3.1-lacZ (gift from Dr. Mesaeli, University of Manitoba). Cells
were harvested 48 h post-transfection using Nonidet P-40 (NP-40)
lysis buffer (1 M Tris, 10% NP-40, 50 mM dithiothreitol (DTT), pH 7.8),
and the luciferase activity was measured in luciferase assay buffer
(20 mM Tricine, 1.07 mM MgCO3, 2.67 mM MgSO4, 0.1 mM EDTA,
33.3 mM DTT, 270 μM coenzyme A, 470 μM beetle luciferin (Pro-
mega), 530 μM ATP) using a Lumat LB 9507 luminometer. β-
Galactosidase activity was measured using a spectrophotometer
(MRX TC Revelation plate reader, Dynex Technologies) at 410 nm
and was used to normalize the luciferase results to the transfection
efﬁciency.
2.8. Cell cycle analysis
5×105 HUVECs were infected at 250 MOI and grown in 175 cm2
tissue culture ﬂasks for 48 h prior to analysis. Alternatively, 3×105
LECs were transfected with siRNA and allowed to grow for 24 h in
ﬁbronectin (Sigma) coated 6-well tissue culture plates. The cells were
then trypsinized and re-plated into ﬁbronectin coated 6-well tissue
culture plates at a lower density (1.5×105 cells per well) and
incubated for 24 h prior to harvest. Cells were trypsinized and ﬁxed in
ice-cold 70% ethanol for 2 h and pelleted at 200×g for 5 min at 4 °C.
The cells were then washed once with 1× PBS, pelleted at 200×g and
stained for 30 min at room temperature in PI staining solution (0.1%
PBT, 0.5 mg/ml RNase A, 0.5 mg/ml propidium iodide). 104 Gated cells
were counted using a BD FACSCalibur and the gates were arranged
using the FL2-A vs. FL2-W plot to exclude doublets. The data were
analyzed using FlowJo software (Tree Star, Inc.) and quantiﬁed using
Origin 8 software.
2.9. Statistical analysis
Statistical analysis for all experiments was performed using Origin
8 software. A paired Student's t-test was used to analyze groups
containing two samples, whereas a one-way ANOVA analysis was
used to analyze groups containing multiple samples. Signiﬁcant
differences were determined for p-values less than 0.05.
3. Results
3.1. The PROX1 homeodomain is not required to activate Ccne1
promoter expression
To determine the molecular mechanism by which PROX1 activates
Ccne1 transcription, we generated expression constructs of Prox1 in
which different putative functional domains were either mutated orFig. 4. PROX1 transcriptional activation of the Ccne1 promoter is mediated through two E2F-b
as well as the E2FI and E2FX sites was used for luciferase reporter gene assays. Both E2F sites w
The basal transcription of the mutE2FI promoter was not signiﬁcantly different from that of t
promoter was signiﬁcantly higher than the control but was reduced when compared to the w
either (C) the 206-bp mutE2FI or (D) the 206-bp mutE2FX promoters as compared to the em
mediated transcription of Cyclin E1. *Indicates a signiﬁcant difference from pGL3-basic, and #
a signiﬁcant difference in promoter activity between cells transfected with wild-type PROX1
signiﬁcant difference in fold induction by PROX1 (WT) between the wild-type 206-bp Ccn
promoters at a p-valueb0.05.deleted (Fig. 1A). The relative expression levels of the different PROX1
proteins were similar with the exception of the HDPD2-deleted
(HDPD2Δ) protein; its expression was consistently found to be
elevated (Fig. 1B and Supplementary Fig. S1). The mutant PROX1
proteins, except for the PD1 domain deletion (PD1Δ) construct, were
localized to the nucleus and had a similar pattern to that observed for
the wild-type (WT) PROX1 protein (Fig. 1C–E and data not shown). In
PROX1, the NLS is located at amino acids 15–19 (KRRRV), which is
outside of the PD1 domain (aa 158–269) (Fig. 1A). No other potential
NLS are predicted to exist in PROX1 by either in silico analysis or
experimentally. The PD1Δ version of PROX1 is found in the cytoplasm
of untreated cells, although it retains the NLS. Therefore, we
hypothesized that PD1Δ PROX1 may still be targeted to the nucleus.
We postulated that once in the nucleus, this mutant version of PROX1
is rapidly exported and that this rapid export accounts for the mutant
protein's localization to the cytoplasm as compared to the nuclear
localized WT PROX1 (Fig. 1D and E). To test this hypothesis, we
treated the cells with leptomycin B, which blocks nuclear export and
therefore results in the retention of nuclear targeted proteins. Indeed,
after leptomycin B treatment, we determined that the PD1Δ version of
PROX1 was localized to the nucleus in a similar manner to wild-type
PROX1 (Fig. 1G and H).
Surprisingly, theWT PROX1 and the homeodomain-deleted (HDΔ)
PROX1 proteins similarly activated transcription from the 1 kb Ccne1
promoter in HEK 293 cells (Fig. 2A). Given that the homeodomain was
not necessary for PROX1-mediated activation of Ccne1 transcription,
we then sought to determine which domains of PROX1 were required
for this function. Although the Prospero domain 2-deleted (PD2Δ)
and the homeoprospero domain 2-deleted (HDPD2Δ) versions of
PROX1 did signiﬁcantly activate transcription of the 1-kb Ccne1
promoter, their levels of induction were signiﬁcantly lower than for
either the wild-type or the HDΔ proteins (Fig. 2A). The reduced
potency of the PD2Δ construct in activating this promoter could result
from the decreased level of expression and not directly due to the loss
of the PD2 domain. In contrast, despite signiﬁcantly elevated levels of
expression, the HDPD2Δ construct was not as effective as wild-type
PROX1 in activating the Ccne1 promoter. The NR boxes were not
required since their deletion did not alter the ability of PROX1 to
activate the Ccne1 promoter (Fig. 2B). Deletion of the PD1 domain
modestly decreased Ccne1 activation (Fig. 2C). This reduction may
result from the decreased level of PD1Δ protein expression as
compared to WT PROX1 (data not shown).
To determine whether our DNA-binding-deﬁcient PROX1 con-
structs were in fact unable to bind DNA, we conducted luciferase
assays using the mouse FGFR-3 promoter. This promoter was
previously demonstrated to be activated by PROX1 directly binding
to DNA [21]. In contrast to the Ccne1 promoter, unlike WT PROX1,
neither the HDΔ version nor the 623WFEEFR628 DNA-binding mutant
was able to signiﬁcantly activate the FGFR-3 promoter in HEK 293 cells
(Fig. 2D). To determinewhether these versions of PROX1 bind directly
to DNA, we created recombinant protein versions of WT,
623WFEEFR628 DNA-binding mutant, and HDΔ PROX1 using the
pMal expression system (Supplementary Fig. S2A). We used these
recombinant proteins in electrophoretic mobility shift assays (EMSA)
to measure their ability to bind to putative binding sites located in the
FGFR-3 promoter [21]. We observed a gel shift with WT PROX1, but
not with either the 623WFEEFR628 DNA-binding mutant or the HDΔinding sites. (A) A region of the Ccne1 promoter containing the transcriptional start site
eremutated individually in the 206-bp Ccne1 promoter (mutations shown in bold). (B)
he empty pGL3-basic (pGL3) control. In contrast, the basal transcription of the mutE2FX
ild-type 206-bp Ccne1 promoter. Wild-type PROX1 (WT) did not signiﬁcantly activate
pty pGL3-basic control. This demonstrates that both E2F sites are required for PROX1-
indicates a signiﬁcant difference from the 206-bp Ccne1 promoter at pb0.05. ♦ Indicates
(WT) and the empty expression vector control (Empty) at a p-valueb0.05.● Indicates a
e1 promoter and the pGL3-basic (pGL3), 206 bp mutE2FI and 206-bp mutE2FX Ccne1
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there was a supershift in the presence of an anti-PROX1 antibody but
not control IgG. The PROX1mutants that were unable to bind DNA are
still able to activate transcription of the Ccne1 promoter reporter
construct (Fig. 2A). Thus, these results demonstrate that PROX1 may
activate Ccne1 transcription independent of binding to DNA.
3.2. Characterization of transcriptional properties of two different DNA-
binding mutants
A previous report, using a PROX1 DNA-binding mutant
(623WFSAFA628) in U2OS osteosarcoma cells, suggested that PROX1-
mediated regulation of Ccne1 transcription was DNA-binding-depen-
dent [18]. Conversely, our PROX1 homeodomain-deleted construct,
which lacks the entire 60-amino-acid homeodomain and is unable to
bind DNA, was still able to activate expression of a Ccne1 reporter
construct in both HEK 293 cells and U2OS cells (Fig. 2A and
Supplementary Fig. S3). To address the discrepancy between these
two ﬁndings, we used the 623WFEEFR628 DNA-binding mutant and
directly compared the ability of the 623WFEEFR628 and 623WFSAFA628
DNA-binding domain mutants to activate Ccne1 transcription in both
cell types. In our DNA-binding mutant construct, the sequence of the
third helix of the homeodomain, which is involved in DNA binding
was mutated from 623WFSNFR628 to 623WFEEFR628. This mutant
protein was stably expressed, localized to the nucleus, andwas unable
to activate expression of the FGFR-3 promoter (Fig. 2D). As well, weFig. 5. PROX1 regulates CYCLIN E1 expression in human primary endothelial cells.(A)
(homeoprospero domain-2-deleted Prox1), or EGFP at 250 MOI followed by Western blo
signiﬁcantly increased CYCLIN E1 levels as compared to the EGFP control. (C) PROX1 expres
measured byWestern blotting. (D) We observed a 58.5% decrease in the protein levels of CYC
p-valueb0.05.generated the previously reported DNA-binding domain mutant in
which 623WFSNFR628 was changed to 623WFSAFA628 [18]. In HEK 293
cells, we observed that both mutant constructs signiﬁcantly activated
the 1-kb Ccne1 promoter (Fig. 3A). In contrast, in U2OS cells, the
623WFSAFA628 mutant did not activate the 1-kb Ccne1 promoter
whereas the 623WFEEFR628 mutant still signiﬁcantly increased its
expression (Fig. 3B). To further characterize this cell-type-speciﬁc
difference, we examined the expression and localization of both DNA-
binding domain mutations via Western blotting and immunocyto-
chemistry in both HEK 293 and U2OS cells. By Western blotting, we
determined that the 623WFEEFR628 DNA-binding mutant was
expressed at a higher level than either wild-type PROX1 or the
623WFSAFA628 DNA-binding mutant in both HEK 293 and U2OS cells
(Supplementary Fig. S4). This difference in expression may account
for some of the observed functional differences between these two
mutant constructs. In HEK 293 cells, expression of both constructs was
generally restricted to the nucleus (Fig. 3C, E). Surprisingly, in U2OS
cells, the 623WFSAFA628 mutant protein was localized to the
cytoplasm as well as the nucleus (Fig. 3D), whereas the 623WFEEFR628
mutant protein was localized solely to the nucleus (Fig. 3F). We
quantiﬁed the subcellular localization of PROX1 and noted that a
signiﬁcant proportion of U2OS cells transfected with the
623
WFSAFA628
mutant had both cytoplasmic and nuclear localization (Fig. 3H); this
cytoplasmic localization was much less evident in the HEK 293 cells
(Fig. 3G) and was not evident for the 623WFEEFR628 mutant protein
expressed in either cell type. As well, we demonstrated a moreHUVECs were infected with adenovirus encoding WT (wild-type Prox1), HDPD2Δ
tting to measure the protein levels of CYCLIN E1. (B) Both WT and HDPD2Δ PROX1
sion was decreased by siRNA-mediated knockdown in LECs and CYCLIN E1 levels were
LIN E1 following PROX1 knockdown. *Denotes a signiﬁcant difference from control at a
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than in HEK 293 cells (Fig. 3C, D). This difference in subcellular
localization could explain the inability of the 623WFSAFA628 mutant to
activate the Ccne1 promoter in U2OS cells. Taken together, these
results show that the 623WFSAFA628 mutation affected the subcellular
localization of PROX1 in a cell-type-speciﬁc manner whereas the
623WFEEFR628 mutation did not.
3.3. PROX1 activates the Ccne1 promoter via proximal E2F-binding sites
Two different versions of the Ccne1 promoter were generated in
order to determine the speciﬁc promoter regions that were required
for PROX1-mediated activation: a 1-kb version and a 206-bp version,
which contains two proximal E2F-binding sites on either side of the
transcriptional start site (Fig. 4A) [39]. PROX1 similarly activated
expression of both versions of the promoter, but we observed that the
basal transcriptional activity of the 1-kb Ccne1 promoter as compared
to the 206-bp Ccne1 promoter was signiﬁcantly increased (data not
shown). We then proceeded to mutate the E2F-binding sites within
the 206-bp Ccne1 promoter (Fig. 4B–D). Upon mutating the upstream
E2F site, known as the E2FI site [37], and the downstream E2F site,
known as the E2FX site [43], we observed a decrease in the basal
transcription level as compared to the WT 206-bp promoter (Fig. 4B).
This decrease was greater with the mutE2FI than the mutE2FX
promoter (Fig. 4B). We then determined that PROX1 did not
signiﬁcantly induce either the mutE2FI (Fig. 4C) or the mutE2FX
promoters (Fig. 4D) as compared to the empty pGL3 control,
indicating that PROX1 regulation of Ccne1 transcription requires
both E2F sites found in the proximal promoter region.Fig. 6. PROX1 regulates the lymphatic endothelial cell cycle. To measure the effect of either P
with BrdU for 45 min and BrdU-positive cells were counted to determine the proportion of ce
of S phase cells in WT-infected cells, whereas we consistently observed a signiﬁcant decrea
proportion of S phase cells in LECs transfected with Prox1 siRNA. Similarly, HUVECs and LECs
the proportion of cells in each phase of the cell cycle. (B) In HUVECs infected at 250 MOI, we
increase in S phase cells inWT-infected cells as compared to the EGFP-infected control cells. (
phase cells in PROX1 knockdown cells as compared to control siRNA-transfected cells and
difference from EGFP or control siRNA at a p-valueb0.05.3.4. PROX1 alters cell cycle progression in venous and lymphatic
endothelial cells
Next, we tested whether overexpression of PROX1 or loss of
PROX1 in endothelial cells inﬂuenced CYCLIN E1 protein levels and
progression through the cell cycle. HUVECs are venous endothelial
cells which do not express endogenous WT PROX1 (Supplementary
Fig. S6) but can be differentiated into a LEC-like phenotype upon
adenoviral-mediated expression of WT PROX1 [17,18]. HUVECs were
infected at 250 MOI with either Ad-Prox1 or Ad-HDPD2Δ and were
subsequently harvested for Western blotting to measure CYCLIN E1
expression. We observed that both WT and HDPD2Δ overexpression
signiﬁcantly increased levels of CYCLIN E1 when compared to EGFP
controls (Fig. 5A, B). LECs were then transfectedwith PROX1 siRNA for
48 h followed by Western blotting to measure CYCLIN E1 levels. The
level of PROX1 protein was reduced N90% by siRNA transfection as
compared to the non-targeting control (Supplementary Fig. 3). We
determined that CYCLIN E1 expression was signiﬁcantly decreased to
58.5% when PROX1 expression was knocked down supporting a role
for PROX1 in controlling CCNE1 expression (Fig. 5C, D).
To assess the effects of ectopic or aberrant PROX1 expression on the
endothelial cell cycle, we ﬁrst analyzed the effects of expressing PROX1
and HDPD2Δ in HUVECs. At 250 MOI, we determined that ectopic
expression of PROX1 did not signiﬁcantly increase the percentage of
HUVECs labeledwithBrdUor PCNA relative to the EGFP control-infected
cells (Fig. 6A and Supplementary Fig. S7A). In contrast,we observed that
expression of HDPD2Δ consistently decreased the proportion of cells
labeled with either BrdU or PCNA compared to EGFP and WT PROX1
infected cells (Fig. 6A and Supplementary Fig. S7A). We then comparedROX1 overexpression or loss of PROX1 on the cell cycle, HUVECs and LECs were labeled
lls in S phase. (A) At 250MOI, we observed that there was no increase in the proportion
se in HDPD2Δ-infected cells. (C) In contrast, we observed a signiﬁcant decrease in the
were labeled with propidium iodide and the DNA content was measured to determine
observed a signiﬁcant decrease in S phase cells infected with HDPD2Δ, but observed no
D) In LECs transfected with siRNA, we noted a signiﬁcant decrease in the proportion of S
a signiﬁcant increase in cells in the G1 phase of the cell cycle. *Indicates a signiﬁcant
Fig. 7. Proposed model of PROX1-mediated activation of the LEC cell cycle.Upon stimulation by mitogens such as VEGF-C/D or FGF, LECs progress from G1 to S phase of the cell cycle.
Loss of PROX1 through siRNA knockdown slows this progression and causes the cells to accumulate in G1.
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adenovirus-infected HUVECs, there was no signiﬁcant increase in the
amount of S phase cells between EGFP and WT, but there was a
signiﬁcant decrease in S phase cells between HDPD2Δ- and EGFP/WT-
infected cells (Fig. 6B and Supplementary Fig. 7B) consistent with BrdU
and PCNA results. Following PROX1 knockdown in LECs, we observed a
signiﬁcant decrease in theproportion of S phase cells as compared to the
control siRNA-transfected cells (Fig. 6C, D and Supplementary Fig. 7C).
We also observed a signiﬁcant increase in the proportion of cells in the
G1 phase of the cell cycle (Fig. 6D). Taken together, these ﬁndings
indicate that PROX1 is required for normal entry of LECs into S phase of
the cell cycle.
4. Discussion
PROX1 is an essential regulator of the development of many diverse
tissues such as the lens, liver, and lymphatics [4–6]. PROX1 has been
shown to repress the expression of its target genes via a DNA-binding-
independent mechanism and activate expression of other targets via a
mechanism dependent on DNA binding [20,21]. Our study shows that
PROX1 may activate transcription independent of binding to DNA. We
have also demonstrated a role for the PD1 domain in regulating PROX1's
subcellular localization. Our results have elucidated a potential role for
PROX1 in regulating the lymphatic endothelial cell cycle.
We characterized the domains of the protein that are necessary for
PROX1-mediated activation of the Ccne1 promoter by mutating or
deleting key regions. Surprisingly, we determined that the home-
odomain was not required for PROX1-mediated activation of Ccne1
transcription. Unexpectedly, we found that the PD1Δ protein was
localized to both the nucleus and the cytoplasmdespite the fact that this
deletion mutant still retained the endogenous PROX1 nuclear localiza-
tion signal. To test whether increased nuclear export resulted in the
cytoplasmic localization of PD1Δ protein, we treated the cells with the
nuclear export inhibitor leptomycin B. We observed that PD1Δ was
retained in the nucleus upon leptomycin B treatment, suggesting a new
role for the PD1 domain as a nuclear export signal mask.
We also determined that PROX1 activated the Ccne1 promoter
through functional domains that are distinct from those it uses to co-
repress the CYP7α-hydroxylase gene. It was previously shown that
PROX1binds to LRH-1 andHNF4α via itsNRboxes, primarilyNR1, and isthereby targeted to the CYP7α-hydroxylase promoter [20]. The Ccne1
promoter also contains a LRH-1-binding site located at position−554,
butwhen this sitewasdeleted, therewasnochange in PROX1's ability to
activate Ccne1 [39]. Moreover, we created a version of PROX1 in which
both NR boxes were deleted (dblNRΔ) and determined that this
construct was still fully capable of activating expression of Ccne1. We
conclude that PROX1 activates Ccne1 transcription independent of
binding to DNA, but not via binding to nuclear receptors through the NR
boxes. The exact mechanism by which PROX1 binds to transcriptional
complexes at the Ccne1 promoter remains to be elucidated.
We established that PROX1 was able to activate a 206-bp version
of the Ccne1 promoter, which contains two E2F-binding sites located
on either side of the transcription start site [37,38]. We then
proceeded to mutate each of the E2F-binding sites in the 206-bp
Ccne1 promoter. We observed that the basal transcription of both the
mutE2FI and the mutE2FX promoters was decreased when compared
to the WT 206-bp promoter although this decrease was greater with
the mutE2FI promoter. PROX1 was unable to induce expression of
either themutE2FI or themutE2FX promoters indicating that both E2F
sites located adjacent to the transcriptional start sight are required for
PROX1 mediated activation.
In Drosophila, Prospero has been shown to regulate the expression
of CycE in longitudinal glia and PROX1 can induce the expression of
CCNE1 in HUVECs [18,44]. In contrast to the previous report by
Petrova et al. [18], which showed that PROX1 activated Ccne1
expression through a DNA-binding-dependent mechanism, we have
determined that PROX1 activates the Ccne1 promoter through a DNA-
binding-independent mechanism. To address this important discrep-
ancy, we compared the expression, subcellular localization, and
transcriptional potential of two different DNA-binding domain
mutants. We observed that both of these DNA-binding mutants
were able to signiﬁcantly induce expression of the 1-kb Ccne1
promoter in HEK 293 cells. Conversely, when we repeated the same
assays in U2OS cells, we observed that the 623WFSAFA628 DNA-
binding mutant was unable to activate the Ccne1 promoter [18].
However, the 623WFEEFR628 DNA-binding mutant was able to
signiﬁcantly activate Ccne1 promoter expression in U2OS cells. In
addition, both the HDΔ and the 623WFEEFR628 mutant proteins were
unable to activate expression of FGFR-3, a direct PROX1 target [21].
We conﬁrmed that neither of these constructs were able to bind
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that cell-type-speciﬁc partners are required for PROX1 function in
these assays and that the 623WFSAFA628 mutant protein is unable to
bind to them. In addition, the different levels of protein expression
seen for the two mutants could affect their ability to regulate
transcription of target genes.
In U2OS cells, we detected a pronounced cytoplasmic localization
of the 623WFSAFA628 mutant, but not the 623WFEEFR628 mutant,
which could account for the cell-type-speciﬁc reduction in transcrip-
tional activity. We also detected a difference in the predicted
molecular weights of these proteins when the two proteins were
expressed in either cell type (Supplementary Fig. S4). This difference
in size could be due to loss of a post-translational modiﬁcation or
misfolding, which may inhibit essential protein–protein interactions
or contribute to the instability and loss of function of the protein.
In support of our reporter gene expression data, we determined
that overexpression of PROX1 and the HDPD2Δ mutant in HUVECs
resulted in increased levels of CCNE1 protein. Furthermore, we
demonstrated that knockdown of PROX1 in LECs reduced CCNE1
levels. In HUVECs, increasing PROX1 expression did not observably
affect endothelial cell cycle progression. It is possible that the
increased CCNE1 expression induced by PROX1 was not sufﬁcient to
signiﬁcantly alter endothelial proliferation since these cells were
unsynchronized and serum stimulated. In contrast, overexpression of
the HDPD2Δ mutant signiﬁcantly decreased the proportion of
proliferating cells as measured by BrdU labeling, PCNA staining, and
ﬂow cytometry. We propose that HDPD2Δ may function in a
dominant negative manner whereby this mutant protein sequesters
PROX1 binding partners that are necessary for proper cell cycle
regulation. Surprisingly, HDPD2Δ was still able to signiﬁcantly
increase the amount of CCNE1 protein in infected HUVECs. This
ﬁnding implies that PROX1 regulation of CCNE1may be necessary, but
not sufﬁcient to drive the endothelial cell cycle, and that other PROX1
targets or cell cycle regulatory molecules could also be involved. We
have demonstrated that PROX1-mediated regulation of Ccne1 is
through two E2F-binding sites. E2F proteins are known regulators of
many cell cycle regulatory genes and could be a common mechanism
for PROX1-mediated cell cycle regulation. Loss of PROX1 function in
LECs consistently resulted in a decreased percentage of cells in S phase
and an increased proportion in G1 phase demonstrating that PROX1 is
required for normal LEC proliferation.
Based on the results we have presented, we propose a model for
PROX1-mediated regulation of the lymphatic endothelial cell cycle
(Fig. 7). Upon mitogen stimulation from ligands such as VEGF-C/D or
FGF, LECs enter into the cell cycle and the proportion of cells in S phase
is increased. Loss of PROX1 through siRNA knockdown disrupts cell
cycle progression and results in decreased G1 to S phase progression.
For the ﬁrst time, our study clearly demonstrates that PROX1
activates transcription of a key cell cycle regulatory gene independent of
its ability to bind toDNA. PROX1 levels in endothelial cells are critical for
determining cell fate and for stimulating cell cycle progression. In
HUVECs, the HDPD2Δmutant was able to activate Ccne1 at the protein
level but overall it blocked cellular proliferation. This mutant could lead
to new approaches to controlling endothelial cell growth in vivo. In the
future, we will identify PROX1-binding partners at the Ccne1 promoter
and determine whether these associations are regulated by changes in
the post-translational modiﬁcations of PROX1. This study provides a
strong foundation for a novel role for PROX1 inmediating the lymphatic
endothelial cell cycle.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbamcr.2010.10.015.
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